Custom-Cell Products: Diversified In Vitro Models - The author outlines the need for custom-cell products. - BioPharm International


Custom-Cell Products: Diversified In Vitro Models
The author outlines the need for custom-cell products.

BioPharm International
Volume 26, Issue 4, pp. 58-59

Photo Credit: luismmolina/Getty Images
Pharmaceutical researchers are continuously searching for the ideal model to understand the biotransformation and clearance of their novel drug compounds. The use of in vitro models in early-stage drug development can facilitate elimination of unsuitable new chemical entities (NCEs) before they ever reach clinical trials, the most costly and resource-intensive portion of the drug development process. The goal is to create in vitro models that best represent physiological conditions and retain stable cellular functions to better predict in vivo effects.


Liver cell co-cultures can offer a more comprehensive in vitro model to study the effects of intercellular signaling on xenobiotic metabolism. Non-parenchymal cells (NPC) of the liver such as Kupffer, sinusoidal, endothelial, and stellate cells can be co-cultured with hepatocytes to more accurately mimic in vivo conditions.

Kupffer cells are a type of macrophage located within the liver sinusoid that are of particular interest because of their key role in the modulation of drug-metabolizing enzymes following immunological response. Hepatocyte/Kupffer cell co-cultures can be seeded at ratios with increasing Kupffer cell content to allow investigators to compare inflammation versus normal-state response. Stimulation of the co-cultures with lipopolysaccharide (LPS) results in the release of a variety of soluble factors, such as nitric oxide (NO) or pro-inflammatory cytokines, such as IL-6 and TNF-α. The response to inflammation and infection can lead to altered gene expression, down-regulation of cytochrome P450 (CYP) enzymes, and depression of the mechanisms underlying drug clearance.

The use of hepatocyte/Kupffer cell co-cultures is also important in the screening of therapeutic proteins and biologics. These drugs are more heterogeneous in composition, follow different pathways of elimination, and have greater potential to elicit an immune response. Their impact on CYP enzyme suppression and the potential to cause small molecule toxicity should be thoroughly studied before reaching clinical trials.

Other advantages to culturing hepatocytes with NPCs are longer maintenance in culture and higher liver-specific function. Fresh and cryopreserved hepatocytes and non-parenchymal cells from the same donor or pool of donors allow researchers to reconstitute compatible cells in a physiologically relevant format that is most appropriate for their experiment.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here